LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

185.91 -2.06

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

180.91

Max

193.2

Galvenie mērījumi

By Trading Economics

Ienākumi

262M

-15M

Pārdošana

1.6M

996M

EPS

-0.3

Peļņas marža

-1.486

Darbinieki

18,300

EBITDA

-11M

187M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+9.77% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

478M

9B

Iepriekšējā atvēršanas cena

187.97

Iepriekšējā slēgšanas cena

185.91

Ziņu noskaņojums

By Acuity

66%

34%

289 / 344 Rangs Healthcare

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūn. 23:36 UTC

Peļņas

Correction to Oracle Reports Higher 4Q Profit Article

2026. g. 10. jūn. 23:19 UTC

Karstas akcijas

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. g. 10. jūn. 23:09 UTC

Galvenie tirgus virzītāji

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. g. 10. jūn. 23:04 UTC

Peļņas

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. g. 10. jūn. 20:44 UTC

Galvenie tirgus virzītāji

Caterpillar Raises Quarterly Dividend 8%

2026. g. 10. jūn. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Should Take No Options Off The Table

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. g. 10. jūn. 23:47 UTC

Tirgus saruna

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. g. 10. jūn. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. g. 10. jūn. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 10. jūn. 23:32 UTC

Tirgus saruna

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. g. 10. jūn. 23:20 UTC

Tirgus saruna

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. g. 10. jūn. 22:05 UTC

Tirgus saruna

Correction to Bank of Canada Stays on Hold Market Talk

2026. g. 10. jūn. 21:57 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:52 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:35 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:22 UTC

Peļņas

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. jūn. 20:39 UTC

Tirgus saruna
Peļņas

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. g. 10. jūn. 20:34 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Peļņas

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna
Peļņas

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

9.77% augšup

Prognoze 12 mēnešiem

Vidējais 208.4 USD  9.77%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

9

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

289 / 344 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat